NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Frequently asked questions
What sector does NeoGenomics, Inc (NEO) operate in?
NeoGenomics, Inc belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is NeoGenomics, Inc (NEO) current stock price?
As of the latest data, NeoGenomics, Inc stock price is $18.94, with a previous close of $18.89. NeoGenomics, Inc gained $0.05 in the last trading session, representing a 0.26% increase.
What is NeoGenomics, Inc (NEO) current market capitalization?
NeoGenomics, Inc market cap is approximately 2.47 billion.
What is NeoGenomics, Inc (NEO) Earnings Per Share (EPS)?
The trailing EPS is -$0.39, and the forward EPS is $0.34.
What is NeoGenomics, Inc (NEO) EBITDA?
NeoGenomics, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 18.82 million.
Does NeoGenomics, Inc (NEO) pay dividends?
No. NeoGenomics, Inc does not pay a dividend.
How did NeoGenomics, Inc (NEO) perform in its most recent earnings report?
In the last report (June 30, 2026), NeoGenomics, Inc posted an EPS surprise of 83.33% and a revenue surprise of 2.37%.
When is NeoGenomics, Inc (NEO) next earnings report?
NeoGenomics, Inc is expected to release its next earnings report on September 30, 2026.
What is NeoGenomics, Inc (NEO) beta (volatility) score?
NeoGenomics, Inc has a beta of 1.730, suggesting it is more volatile than the market.
